ILMN
The plot thickens
Illumina is adding three new companies to its Billion Cell Atlas alliance, and the headline name here is Formation Bio — the AI-native drug developer that’s basically trying to make drug discovery less like wandering around a dark warehouse with a flashlight.
The pitch is simple: Illumina brings the giant genome-wide perturbation data set, and the alliance members bring the algorithms, drug-design chops, and development pipelines. Together, they’re trying to turn all that biological spaghetti into more precise medicines that can actually make it to approval.
Why investors should care
This isn’t just a feel-good partnership press release with a shiny AI sticker slapped on it. It’s Illumina trying to make its data platform feel indispensable, which matters because the sequencing business is great — but the real dream is to be embedded deeper into the drug-development workflow.
If that works, Illumina gets to play a bigger game than selling instruments and consumables. It becomes part of the infrastructure for how future drugs get built, tested, and maybe even approved.
Big picture
AI drug discovery has become the market’s favorite science fair project, but Illumina’s angle is a little different: it’s selling the raw fuel. If its data ends up being the thing that helps pharma teams find better candidates faster, that’s a nice long-term moat. And in biotech, moats are usually what separate the science experiment from the business.